Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

2 Apr 2009 07:00

RNS Number : 9670P
Intercede Group PLC
02 April 2009
 



APRIL 2009

INTERCEDE GROUP PLC

("Intercede" or "the Company")

Trading Update for the Full Year to 31 March 2009

Further to Intercede's Trading Update on 5 February 2009, we are pleased to report that the Company is continuing to experience high levels of interest in and demand for its MyID technology

Pre audit indications of the results for the year ended 31 March 2009 are that revenues are likely to be more tha90ahead of the previous year's reported revenues of £2.8m. A full year profit has been achieved for the first time in the Group's history and earnings before interest and tax are anticipated to exceed £1m. As a result of this performance, the cash balance at 31 March 2009 was £3.7m, compared to £1.2m at the same time last year.

This acceleration in Intercede's growth reflects the continued momentum from the Company's involvement in an increasing number of projects around the world with a consequential increase in revenues from software license sales, associated support & maintenance and the delivery of ongoing professional services assistance. 

Intercede Chairman and Chief Executive Richard Parris said, "I am pleased to report a strengthening in demand for Intercede's products from both national governments and large enterprise customers. This is generating attractive financial returns at a time when general economic conditions around the world are difficult."

Intercede expects to announce its full year results for the year ended 31 March 2009 by mid June 2009.

ENQUIRIES

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. +44 (0)20 7600 1658

Charles Cunningham

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7337 1509

About Intercede

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management.

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a programme with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

Intercede and MyID are registered trademarks or trademarks in the UK, US and/or other countries. For more information visit http://www.intercede.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSSLFMFSUSEDL
Date   Source Headline
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20247:00 amRNSTransaction in Own Shares
14th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20247:00 amRNSTransaction in Own Shares
8th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSNotice of Results & Investor Presentation
25th Oct 20247:00 amRNSShare Buyback Programme
11th Oct 20248:38 amRNSDirector/PDMR Shareholding
8th Oct 20247:00 amRNSTrading Update
1st Oct 20247:00 amRNSNotification of Trading Update and H1 FY25 Results
30th Sep 20247:00 amRNSContract Orders and Renewals
25th Sep 202412:51 pmRNSResult of AGM
20th Sep 202411:45 amRNSDirector/PDMR Shareholding
18th Sep 20247:00 amRNSContract Orders and Renewals
2nd Sep 20247:00 amRNSContract Orders and Subscription Renewals
30th Aug 20247:00 amRNSNotice of AGM and Publication of Annual Report
4th Jul 20243:58 pmRNSIssue of Equity & Total Voting Rights
28th Jun 20243:49 pmRNSIssue of Equity & Total Voting Rights
26th Jun 20247:00 amRNSPartnership with Carahsoft Technology Corp
19th Jun 20246:25 pmRNSHolding(s) in Company
18th Jun 20249:17 amRNSHolding(s) in Company
18th Jun 20247:15 amRNSDirector/PDMR Shareholding and Issue of Equity
18th Jun 20247:00 amRNSFinal Results
5th Jun 20247:00 amRNSNotice of Results & Investor Presentation
16th May 202412:00 pmRNSCapital Markets Day - Agenda Update
14th May 20246:17 pmRNSShare Incentive Scheme
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.